Drug Trial Radar · NCT06855160
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
911
Planned (sponsor's estimate)
Start
Apr 17, 2025
Primary completion
Sep 10, 2026
Study completion Feb 2, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.
Conditions
- Chickenpox
Interventions
Candidate varicella vaccineBiological
Investigational varicella vaccine administered intramuscularly.
Marketed varicella vaccineBiological
Marketed varicella vaccine administered subcutaneously.
MMR vaccineBiological
MMR vaccine administered subcutaneously or intramuscularly.
Hepatitis A vaccineBiological
Hepatitis A vaccine co-administered intramuscularly.
PCV (pneumococcal conjugate vaccine) 13Biological
The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
PCV 20Biological
The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
VaxneuvanceBiological
The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries Vaxneuvancewill only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti- glycoprotein E (gE) Immunoglobulin (IgG)Time frame: At Day 43
- Geometric Mean Concentration (GMC) of anti-VZV gE IgGTime frame: At Day 43
- Percentage of participants with seroresponse to MMR antigensTime frame: At Day 43
- GMC of Anti-measles antibodiesTime frame: At Day 43
- GMC of Anti-mumps antibodiesTime frame: At Day 43
- GMC of Anti-rubella antibodiesTime frame: At Day 43
Locations
22 sites in 7 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Tucson, Arizona · Recruiting
GSK Investigational Site
Huntington Park, California · Recruiting
GSK Investigational Site
Sherman Oaks, California · Recruiting
GSK Investigational Site
Coral Gables, Florida · Recruiting
GSK Investigational Site
Miami Lakes, Florida · Recruiting
GSK Investigational Site
Tampa, Florida · Recruiting
GSK Investigational Site
Idaho Falls, Idaho · Recruiting
GSK Investigational Site
Dayton, Ohio · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Lewisville, Texas · Recruiting
GSK Investigational Site
Mansfield, Texas · Recruiting
GSK Investigational Site
Pharr, Texas · Recruiting
GSK Investigational Site
Richmond, Virginia · Recruiting
GSK Investigational Site
Alken, Belgium · Recruiting
GSK Investigational Site
Tartu, Estonia · Recruiting
GSK Investigational Site
Athens, Greece · Withdrawn
GSK Investigational Site
Athens, Greece · Recruiting
GSK Investigational Site
Thessaloniki, Greece · Recruiting
GSK Investigational Site
Trzebnica, Poland · Recruiting
GSK Investigational Site
Brasov, Romania · Recruiting
GSK Investigational Site
Calarasi, Romania · Recruiting
GSK Investigational Site
Chiang Mai, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.